Clinical Study of Roflumilast Combined with Tiotropium Bromide for Stable Chronic Obstructive Pulmonary Disease
Objective To investigate the clinical efficacy of roflumilas combined with tiotropium bromide for the stable chronic obstructive pulmonary disease(COPD).Methods A total of 90 patients with stable COPD admitted to the Third People's Hospital of Jingzhou from January to December 2022 were selected and divided into the control group and the observation group by the random number table method,with 45 cases in each group.The patients in the two groups were treated with Tiotropium Bromide Powder for Inhalation,on this basis,the patients in the observation group were treated with Roflumilas Tablets orally.Both groups were treated continuously for two months.Results The total effective rate in the observation group was 93.33%,which was significantly higher than 75.56%in the control group(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in one second(FEV1)and FEV1/FVC in the two groups were significantly higher,the 6-minute walk distance(6MWD)was significantly longer,the COPD Assessment Test(CAT)score,tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),leukotriene B4(LTB4)and matrix metalloproteinase-2(MMP-2)levels were significantly lower,tissue inhibitor of metalloproteinase-2(TIMP-2)level was significantly higher(P<0.05),and those in the observation group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(13.33%vs.11.11%,P>0.05).Conclusion Roflumilas combined with tiotropium bromide for stable COPD can effectively improve the lung function and clinical symptoms of patients,decrease the levels of inflammatory factors and fibrosis indexes.
万方数据
维普
